1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chinese Regulators OK BeiGene's Non-Small Cell Lung Cancer Treatment

01/06/2022 | 11:56pm EDT


© MT Newswires 2022
All news about BEIGENE, LTD.
08:39aBEIGENE : Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and G..
PU
08:35aBEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/26BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and ..
BU
05/24Asian ADRs Move Lower in Tuesday Trading
MT
05/17BeiGene to Open Regional Office in Switzerland
MT
05/17BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Swi..
BU
05/17BeiGene, Ltd. Announces the Opening of a New Regional Office in Basel, Switzerland
CI
05/12BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato..
BU
05/11Asian ADRs Move Higher in Wednesday Trading
MT
05/10Asian ADRs Climb Higher in Tuesday Trading
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 438 M - -
Net income 2022 -1 382 M - -
Net cash 2022 2 802 M - -
P/E ratio 2022 -9,16x
Yield 2022 -
Capitalization 13 543 M 13 543 M -
EV / Sales 2022 7,47x
EV / Sales 2023 5,63x
Nbr of Employees 8 300
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | BGNE | US07725L1026 | MarketScreener
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 131,26 $
Average target price 307,42 $
Spread / Average Target 134%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-51.55%13 543
GILEAD SCIENCES, INC.-11.21%80 866
REGENERON PHARMACEUTICALS, INC.8.22%73 638
VERTEX PHARMACEUTICALS22.79%68 965
BIONTECH SE-38.65%38 433
WUXI APPTEC CO., LTD.-22.01%37 870